The NETest, a multigenomic liquid biopsy biomarker for neuroendocrine tumor disease, is an accurate diagnostic, predicts surgical recurrence stratifies disease status

#3225

Introduction: A universal NET liquid biopsy biomarker is required for optimal management of NET disease.

Aim(s): We report a multigenomic NET-specific blood biomarker test assessed over 5 years for diagnostic and surgical utility.

Materials and methods: NETest was evaluated in 2,383 subjects: 1,652 NETs, other cancers (n=475) and controls (n=256). Disease status evaluated by RECIST 1.1. NETest measurement by qPCR (0-100 scale, ULN: <20). Statistics: Mann-Whitney U-test, AUROC analysis, and Chi2 test.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Modlin I

Authors: Modlin I, Kidd M, Drozdov I, Alexandra K,

Keywords: NETest, biomarker, liquid biopsy, diagnostic,